<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="uk">
		<id>http://istoriya.soippo.edu.ua/index.php?action=history&amp;feed=atom&amp;title=The_Annals_Behind_The_Amiloride_Accomplishments</id>
		<title>The Annals Behind The Amiloride Accomplishments - Історія редагувань</title>
		<link rel="self" type="application/atom+xml" href="http://istoriya.soippo.edu.ua/index.php?action=history&amp;feed=atom&amp;title=The_Annals_Behind_The_Amiloride_Accomplishments"/>
		<link rel="alternate" type="text/html" href="http://istoriya.soippo.edu.ua/index.php?title=The_Annals_Behind_The_Amiloride_Accomplishments&amp;action=history"/>
		<updated>2026-06-11T23:39:36Z</updated>
		<subtitle>Історія редагувань цієї сторінки в вікі</subtitle>
		<generator>MediaWiki 1.24.1</generator>

	<entry>
		<id>http://istoriya.soippo.edu.ua/index.php?title=The_Annals_Behind_The_Amiloride_Accomplishments&amp;diff=168294&amp;oldid=prev</id>
		<title>Camel2park: Створена сторінка: 4 �� 2 at the beginning of CSII to 4.9 �� 2.9 at the end of the study (P  the period 4 to 12 hours. The dawn phenomenon was more prevalent in men, with...</title>
		<link rel="alternate" type="text/html" href="http://istoriya.soippo.edu.ua/index.php?title=The_Annals_Behind_The_Amiloride_Accomplishments&amp;diff=168294&amp;oldid=prev"/>
				<updated>2017-04-22T06:33:45Z</updated>
		
		<summary type="html">&lt;p&gt;Створена сторінка: 4 �� 2 at the beginning of CSII to 4.9 �� 2.9 at the end of the study (P  the period 4 to 12 hours. The dawn phenomenon was more prevalent in men, with...&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Нова сторінка&lt;/b&gt;&lt;/p&gt;&lt;div&gt;4 �� 2 at the beginning of CSII to 4.9 �� 2.9 at the end of the study (P  the period 4 to 12 hours. The dawn phenomenon was more prevalent in men, with mean insulin requirements &amp;gt;1 IU/hour (Figure 2). Figure [http://www.selleckchem.com/products/INCB18424.html Ruxolitinib solubility dmso] 2. Average insulin infusion rate per hour at the beginning of CSII therapy and at the end of follow-up (5 months later). Differences (P  correlated with HbA1c at the beginning of CSII therapy (r = .680; P [http://www.selleckchem.com/products/PLX-4032.html Vemurafenib] �� 2; P  improve metabolic [https://en.wikipedia.org/wiki/Amiloride Amiloride] control prior to pregnancy achieved lower levels of HbA1c than the other subjects (6.7 �� 0.7 vs 7.6 �� 0.9%; P&lt;/div&gt;</summary>
		<author><name>Camel2park</name></author>	</entry>

	</feed>